Thioguanine, sold in the United States under the brand name Tabloid, is a chemotherapy medicine used in carefully planned leukemia treatment. It is not the kind of tablet that belongs in a casual “take it and forget it” routine. Thioguanine is powerful, highly individualized, and monitored closely because it can affect the bone marrow, liver, immune system, and more.
For people facing acute myeloid leukemia (AML), a medicine like thioguanine can be one piece of a larger treatment puzzle. The puzzle may be serious, but understanding the medication should not feel like decoding a secret message written in tiny pharmacy font. This guide explains how thioguanine works, what it is used for, how dosing is determined, which side effects deserve immediate attention, and why regular blood tests are part of the plan rather than an annoying side quest.
Thioguanine Quick Facts
- Generic name: Thioguanine, also called 6-thioguanine or 6-TG
- Brand name in the U.S.: Tabloid
- Drug class: Purine analog antimetabolite chemotherapy
- Main use: Remission induction and consolidation treatment for acute nonlymphocytic leukemia, commonly described today as AML
- Dosage form: Oral tablet
- Major safety concerns: Low blood counts, infection, bleeding, liver toxicity, pregnancy risks, and medication interactions
What Is Thioguanine and How Does It Work?
Thioguanine is an antimetabolite, meaning it interferes with the materials cancer cells need to grow and divide. More specifically, it is a purine analog. Purines are building blocks used to make DNA and RNA. Thioguanine resembles one of those building blocks closely enough to sneak into the process, where it disrupts DNA and RNA production.
In plain English, thioguanine hands rapidly dividing leukemia cells a faulty instruction manual. Cancer cells tend to multiply quickly, so they are especially vulnerable when the DNA-copying process goes sideways. Healthy cells can also be affected, particularly fast-growing cells in the bone marrow, digestive tract, and hair follicles. That is why chemotherapy can bring both benefits and side effects in the same very small tablet.
Thioguanine Uses: What Does Tabloid Treat?
Thioguanine is primarily used as part of treatment for acute myeloid leukemia, or AML. Older prescribing materials may use the term “acute nonlymphocytic leukemia,” which generally refers to the same broad family of myeloid leukemias.
Its approved role includes remission induction and remission consolidation. Induction treatment aims to reduce leukemia cells enough to achieve remission. Consolidation treatment follows remission and is intended to reduce the chance that remaining leukemia cells regain momentum.
Thioguanine is often used with other chemotherapy medicines rather than as a solo act. Combination regimens are common in AML because leukemia treatment usually requires several drugs working in different ways. Thioguanine is not generally recommended as long-term maintenance therapy because continuous use can raise the risk of serious liver toxicity.
It is not considered an effective treatment for many other cancers, including most solid tumors, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma. A medication with a dramatic name does not automatically earn an all-access pass to every cancer diagnosis.
Thioguanine Pictures and Tablet Identification
Current U.S. Tabloid labeling describes thioguanine as a round, biconvex white to off-white tablet. The tablet is scored and may carry the imprint T40 on one side. Each branded tablet contains 40 mg of thioguanine.
Tablet appearance can vary if a manufacturer, package, or pharmacy supplier changes. For that reason, never identify a loose pill based only on an online photo, color, or someone’s confident guess at the kitchen table. The prescription bottle label, tablet imprint, pharmacist, and oncology team are safer sources of confirmation. A score line may help with prescribed dosing, but it is not permission to create a new dose plan at home.
Thioguanine Dosing: Why There Is No One-Size-Fits-All Number
Thioguanine dosing depends on the treatment protocol, the person’s body size, blood counts, liver function, cancer response, other medicines, and genetic factors affecting drug metabolism. It is usually taken by mouth, and the total daily dose may be given once daily. Many patients are instructed to take it on a consistent schedule, but the exact routine should come from the oncology team.
Typical Label-Based Starting Dose
For single-agent therapy, prescribing information has historically listed an initial dose of approximately 2 mg per kilogram of body weight per day for adults and children. If there is no clinical improvement after several weeks and blood counts have not dropped significantly, clinicians may cautiously increase the dose. In combination chemotherapy, however, the dose and schedule are determined by the specific AML protocol rather than a generic internet chart.
Genetic Testing Can Change the Plan
Two genes, TPMT and NUDT15, help explain why one person may tolerate thioguanine differently from another. People with reduced or absent activity of either enzyme can accumulate higher levels of active thioguanine metabolites and may develop severe bone marrow suppression at standard doses.
Patients with complete TPMT or NUDT15 deficiency may need a substantially reduced starting dose, sometimes 10% or less of the usual amount. People with partial deficiency may also need dose adjustments based on blood counts and side effects. Genetic testing is useful, but it does not replace routine monitoring. Think of it as an early warning system, not a magical shield.
Missed Dose Guidance
If a dose is missed, do not take two doses together to “catch up.” Contact the oncology clinic or follow the written instructions provided with the treatment plan. Chemotherapy schedules are designed with purpose, and improvising with a double dose is not a bonus round.
Common Thioguanine Side Effects
The most important and common toxicity of thioguanine is myelosuppression, meaning the medication can reduce the bone marrow’s ability to make blood cells. This can lower white blood cells, red blood cells, and platelets.
- Low white blood cells: Higher risk of infection, fever, chills, sore throat, cough, or mouth sores
- Low red blood cells: Tiredness, weakness, dizziness, pale skin, shortness of breath, or reduced exercise tolerance
- Low platelets: Easy bruising, nosebleeds, bleeding gums, tiny red skin spots, or blood in urine or stool
- Digestive effects: Nausea, vomiting, poor appetite, stomach discomfort, diarrhea, or mouth inflammation
- General effects: Fatigue, rash, or feeling generally unwell
Some side effects are manageable with anti-nausea medicine, hydration, nutrition support, mouth care, or schedule changes. Others require urgent laboratory tests, dose holds, transfusions, antibiotics, or additional care. The key is reporting symptoms early rather than trying to win an unwanted toughness contest.
Serious Thioguanine Warnings
Bone Marrow Suppression, Infection, and Bleeding
Thioguanine can lower blood counts enough to cause life-threatening infection or bleeding. Frequent complete blood counts help clinicians spot a decline before it becomes an emergency. Fever can be the first or only sign of infection when white blood cells are low, so patients should follow their cancer center’s fever instructions immediately.
Call the oncology team urgently for fever, chills, unusual bleeding, black or bloody stools, blood in urine, new shortness of breath, severe weakness, or bruising that appears without a clear reason. A temperature of 100.4°F (38°C) or higher is commonly treated as urgent during chemotherapy, but every clinic may have specific instructions.
Liver Toxicity
One of thioguanine’s most significant risks is liver injury, especially with maintenance therapy or long-term continuous use. It can cause vascular damage in the liver and may lead to veno-occlusive disease, portal hypertension, fluid buildup, or other serious complications.
Warning signs include yellowing of the skin or eyes, dark urine, pale stools, pain or tenderness in the upper right abdomen, rapid weight gain, swelling, or an enlarged abdomen. Liver blood tests are usually monitored regularly, especially early in treatment and when other potentially liver-toxic medicines are being used.
Pregnancy and Breastfeeding
Thioguanine can harm a developing fetus. Patients who could become pregnant should discuss reliable contraception and family-planning concerns with their oncology team before treatment begins. Tell the care team immediately about a pregnancy or possible pregnancy. Breastfeeding is generally not recommended while taking thioguanine because of the potential for serious harm to an infant.
Vaccines
Because thioguanine can suppress immune function, live vaccines may not be safe during treatment. Do not receive a vaccine, including travel-related vaccines, without checking with the oncology team first. Family members may also need individualized advice about vaccines and infection precautions.
Thioguanine Drug Interactions
Thioguanine can interact with medications, supplements, and treatments that affect bone marrow function, liver health, or thiopurine metabolism. Patients should provide a complete medication list that includes prescription medicines, over-the-counter drugs, vitamins, herbal products, and supplements. “Natural” does not automatically mean “chemotherapy-friendly.”
Aminosalicylate Medicines
Medicines such as mesalamine, sulfasalazine, and olsalazine may inhibit TPMT activity. This can increase the risk of thioguanine-related bone marrow suppression in some patients. The combination is not automatically forbidden, but it requires careful clinical review and monitoring.
Other Myelosuppressive or Hepatotoxic Medicines
Other chemotherapy drugs, immune-suppressing medicines, or medications that can stress the liver may increase the likelihood of low blood counts or liver problems. The oncology team may adjust treatment timing, laboratory monitoring, or supportive care based on the full regimen.
Allopurinol
Allopurinol may be used during cancer treatment to help manage high uric acid levels caused by rapid tumor cell breakdown. Unlike mercaptopurine and azathioprine, thioguanine does not automatically require a dose reduction simply because allopurinol is used. Still, only the oncology team should make that determination, because the entire treatment regimen matters.
Mercaptopurine and Treatment Resistance
Thioguanine and mercaptopurine are closely related thiopurine medicines. Leukemia that has shown resistance to one may also be resistant to the other. This is less about a routine drug interaction and more about treatment strategy, but it is an important reason oncology history matters.
Monitoring During Thioguanine Treatment
Thioguanine treatment is built around monitoring. The medication may be taken at home, but its safety depends on frequent communication with the cancer team and regular laboratory testing.
- Complete blood counts with white blood cell, hemoglobin, and platelet measurements
- Liver tests, including bilirubin and liver enzymes
- Assessment for fever, bleeding, bruising, jaundice, swelling, or infection symptoms
- Possible TPMT and NUDT15 testing before or during treatment
- Review of all medications, supplements, and vaccinations
Blood work is not bureaucracy. It is the dashboard that helps the oncology team decide whether the medicine is working safely, whether the dose should change, or whether treatment needs a temporary pause.
Practical Tips for Taking Thioguanine Safely
- Take thioguanine exactly as prescribed and at the time directed by the oncology team.
- Ask whether the treatment plan requires taking it with food, without food, or at a particular time of day.
- Keep a written medication list and bring it to appointments.
- Use a thermometer if instructed, and know the clinic’s fever threshold.
- Avoid close contact with people who are sick when blood counts are low.
- Do not start new supplements, pain relievers, antibiotics, or vaccines without approval.
- Store tablets in the original container, away from moisture, children, and pets.
- Ask the pharmacist about safe handling and disposal of unused chemotherapy tablets.
Experiences With Thioguanine: What Patients and Caregivers Often Learn
Living with thioguanine treatment can feel like balancing two calendars at once. One calendar contains ordinary life: school, work, meals, family plans, birthdays, laundry, and the mysterious disappearance of every matching sock in the house. The other calendar contains blood draws, oncology appointments, medication times, refill calls, infection precautions, and the occasional urgent question that cannot wait until Monday morning. Patients and caregivers often find that treatment becomes more manageable once the routine is written down rather than carried entirely in someone’s memory.
A common lesson is that symptoms deserve attention even when they seem small. Fatigue may feel like an expected part of cancer treatment, but suddenly worsening weakness can also signal anemia, infection, dehydration, or another problem worth reporting. Bruising may seem minor until it appears more often than usual. A sore throat may be nothing, or it may be the first clue of infection when white blood cell counts are low. The best approach is not panic; it is prompt communication. Cancer teams would rather answer an early question than manage a late emergency.
Many families also learn the value of a simple tracking system. A notebook, phone reminder, or medication app can record dose times, temperatures, nausea, vomiting, bowel changes, bruising, appetite, and questions for the next visit. This is not about turning life into a spreadsheet with a personality crisis. It is about making patterns easier to spot. For example, a patient may notice nausea is worse at a certain time of day, or that fatigue increases after a particular treatment combination. Those details can help the care team make practical adjustments.
Food and hydration often become part of the conversation. Some people have little appetite during chemotherapy, while others find that small, frequent meals are easier than facing a large plate that suddenly looks like a personal challenge. The oncology team may recommend anti-nausea medicine, hydration strategies, or a referral to a dietitian. The goal is not perfection. It is maintaining strength, avoiding dehydration, and finding foods that are tolerable when taste buds decide to become dramatic critics.
Caregivers often become the unofficial co-pilots of treatment. They may help organize pill bottles, drive to laboratory appointments, notice changes in energy or mood, and keep track of instructions during busy clinic visits. Their role matters, but caregivers also need rest and support. Asking another family member to help with meals, transportation, or errands is not weakness; it is good logistics. Even superheroes need someone to hold the clipboard.
Finally, many people say that confidence grows when they understand the reason behind monitoring. Frequent blood tests can feel repetitive, but they help the treatment team catch falling blood counts and liver changes before those problems become more serious. Thioguanine therapy is not just about swallowing a tablet. It is a coordinated process involving medication, laboratory testing, symptom reporting, supportive care, and careful adjustments. The more patients and caregivers understand that process, the less mysterious it becomesand the easier it is to speak up when something does not feel right.
Final Takeaway
Thioguanine, or Tabloid, is an oral chemotherapy medicine used in selected AML treatment plans. It works by disrupting the DNA and RNA production cancer cells need to multiply, but it can also affect healthy bone marrow and liver tissue. The biggest concerns are low blood counts, infection, bleeding, liver toxicity, genetic differences in TPMT or NUDT15 activity, pregnancy risks, and interactions with other medicines.
Its effectiveness and safety depend on individualized dosing, scheduled laboratory monitoring, and quick communication with the oncology team. The most useful rule is simple: take thioguanine exactly as prescribed, never double a missed dose, and report fever, bleeding, jaundice, unusual bruising, or severe fatigue without delay.